December 17, 2007 - 1:30 p.m.
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
Printer Friendly Version 
December 11, 2007 - 8:02 a.m.
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Printer Friendly Version 
November 28, 2007 - 4:16 p.m.
Gilead Sciences to Present at the NASDAQ 20th Investor Program on Thursday, December 6
Printer Friendly Version 
November 19, 2007 - 4:16 p.m.
Gilead Sciences to Present at the 19th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
Printer Friendly Version 
November 16, 2007 - 1:39 p.m.
Gilead Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis
Printer Friendly Version 
November 07, 2007 - 4:16 p.m.
Gilead Sciences to Present at the 2007 Credit Suisse Healthcare Conference on Wednesday, November 14
Printer Friendly Version 
November 06, 2007 - 8:51 p.m.
Gilead and LG Life Sciences Announce Global License Agreement to Advance Novel Drug Candidates for Treatment of Fibrotic Diseases
Printer Friendly Version 
November 04, 2007 - 5:01 p.m.
Gilead Announces Phase I Data for GS 9190, An Investigational Compound for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
November 02, 2007 - 9:05 a.m.
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Printer Friendly Version 
October 31, 2007 - 4:15 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
October 29, 2007 - 3:02 a.m.
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Printer Friendly Version 
October 24, 2007 - 4:16 p.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
October 23, 2007 - 5:01 p.m.
Gilead Announces New Letairis(TM) (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Printer Friendly Version 
October 22, 2007 - 4:16 p.m.
Gilead Announces Share Repurchase Program
Printer Friendly Version 
October 18, 2007 - 4:25 p.m.
Caroline Dorsa to Join Gilead as Senior Vice President and Chief Financial Officer
Printer Friendly Version 
October 18, 2007 - 4:06 p.m.
Gilead Sciences Announces Third Quarter 2007 Financial Results
Printer Friendly Version 
October 18, 2007 - 12:54 p.m.
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Printer Friendly Version 
October 17, 2007 - 8:03 a.m.
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Printer Friendly Version 
October 11, 2007 - 4:30 p.m.
Gilead Submits Marketing Applications in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
October 10, 2007 - 4:15 p.m.
Gilead Sciences to Release Third Quarter 2007 Financial Results on Thursday, October 18, 2007
Printer Friendly Version 
October 04, 2007 - 1:50 p.m.
Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Printer Friendly Version 
September 24, 2007 - 4:15 p.m.
Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension
Printer Friendly Version 
September 18, 2007 - 4:31 p.m.
Gilead Sciences to Present at the 2007 UBS Global Life Sciences Conference on Tuesday, September 25
Printer Friendly Version 
September 05, 2007 - 4:30 p.m.
Gilead Sciences to Present at the Bear Stearns 20th Annual Healthcare Conference on Tuesday, September 11
Printer Friendly Version 
August 29, 2007 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
August 15, 2007 - 4:16 p.m.
Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease
Printer Friendly Version 
July 31, 2007 - 4:16 p.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
July 23, 2007 - 8:31 a.m.
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Printer Friendly Version 
July 19, 2007 - 4:06 p.m.
Gilead Sciences Announces Second Quarter 2007 Financial Results
Printer Friendly Version 
July 12, 2007 - 4:05 p.m.
Gilead Sciences to Release Second Quarter 2007 Financial Results on Thursday, July 19, 2007
Printer Friendly Version 
July 09, 2007 - 4:32 p.m.
Gilead Announces Expanded Access Program for Aztreonam Lysine for Inhalation for Patients with Cystic Fibrosis
Printer Friendly Version 
June 25, 2007 - 8:31 a.m.
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Printer Friendly Version 
June 21, 2007 - 4:30 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
June 19, 2007 - 8:31 a.m.
Gilead Sciences Completes $1 Billion Stock Repurchase Program
Printer Friendly Version 
June 15, 2007 - 5:25 p.m.
Gilead Sciences to Host Conference Call to Discuss the U.S. Food and Drug Administration Approval of Letairis(TM)
Printer Friendly Version 
June 15, 2007 - 5:20 p.m.
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Printer Friendly Version 
June 06, 2007 - 5:35 p.m.
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Printer Friendly Version 
June 06, 2007 - 4:30 p.m.
Gilead Sciences to Present at the Goldman Sachs 28th Annual Healthcare Conference on Wednesday, June 13
Printer Friendly Version 
May 30, 2007 - 4:31 p.m.
Gilead Sciences' Executive Vice President, Commercial Operations Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
May 29, 2007 - 4:41 p.m.
Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Printer Friendly Version 
May 22, 2007 - 4:16 p.m.
Gilead Sciences to Present at Bank of America's 2007 Healthcare Conference on Wednesday, May 30
Printer Friendly Version 
May 21, 2007 - 12:41 p.m.
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Printer Friendly Version 
May 17, 2007 - 4:16 p.m.
Gilead Sciences' Chief Operating Officer and Chief Financial Officer Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
May 15, 2007 - 4:18 p.m.
Gilead Sciences to Present at Citigroup's 2007 Global Healthcare Conference on Wednesday, May 23
Printer Friendly Version 
May 10, 2007 - 9:02 a.m.
Gilead Sciences Announces Senior Management Promotion
Printer Friendly Version 
May 08, 2007 - 4:18 p.m.
Gilead Board of Directors Approves Two-for-One Stock Split
Printer Friendly Version 
April 25, 2007 - 4:30 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, May 2
Printer Friendly Version 
April 19, 2007 - 4:07 p.m.
Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Printer Friendly Version 
April 18, 2007 - 4:07 p.m.
Gilead Sciences Announces First Quarter 2007 Financial Results
Printer Friendly Version 
April 11, 2007 - 4:30 p.m.
Gilead Sciences to Release First Quarter 2007 Financial Results on Wednesday, April 18, 2007
Printer Friendly Version 
April 05, 2007 - 4:30 p.m.
Gilead Sciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Thursday, April 12
Printer Friendly Version 
March 23, 2007 - 9:03 a.m.
Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency
Printer Friendly Version 
March 15, 2007 - 4:30 p.m.
Gilead Sciences to Present at the Lehman Brothers 10th Annual Global Healthcare Conference on Monday, March 19
Printer Friendly Version 
March 15, 2007 - 4:17 p.m.
Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
Printer Friendly Version 
March 09, 2007 - 9:00 a.m.
Gilead Sciences Announces New Appointments within Executive Team
Printer Friendly Version 
March 08, 2007 - 4:30 p.m.
Gilead Sciences to Present at the Cowen & Company 27th Annual Health Care Conference on Monday, March 12
Printer Friendly Version 
March 01, 2007 - 4:01 p.m.
Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
Printer Friendly Version 
February 23, 2007 - 4:02 p.m.
Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
Printer Friendly Version 
February 16, 2007 - 4:01 p.m.
Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
Printer Friendly Version 
February 08, 2007 - 12:01 a.m.
Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development
Printer Friendly Version 
February 02, 2007 - 7:00 p.m.
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Wednesday, February 7
Printer Friendly Version 
January 31, 2007 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2006 Financial Results
Printer Friendly Version 
January 25, 2007 - 5:02 p.m.
Gilead Sciences Announces Senior Management Promotion
Printer Friendly Version 
January 24, 2007 - 4:29 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2006 Financial Results on Wednesday, January 31, 2007
Printer Friendly Version 
January 23, 2007 - 8:44 a.m.
Carla A. Hills Joins Gilead Sciences' Board of Directors
Printer Friendly Version 
January 04, 2007 - 4:14 p.m.
Gilead Sciences to Present at the 25th Annual JPMorgan Healthcare Conference on Monday, January 8th
Printer Friendly Version 
NASDAQ (US Dollar)
$69.37
 Stock is Up 0.54 (0.78%)
Data as of 02/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote